Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$8.33 USD
+0.37 (4.65%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $8.34 +0.01 (0.12%) 5:18 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
IOVA 8.33 +0.37(4.65%)
Will IOVA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IOVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IOVA
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
IOVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Other News for IOVA
How Is The Market Feeling About Iovance Biotherapeutics?
Interesting IOVA Put And Call Options For March 2025
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics put volume heavy and directionally bearish
7 ‘Death Cross’ Stocks That Could Be Contrarian Buys